Jakuitis Artūras, Statkeviciene Audrone
Kaunas Emergency Medical Service, Pramones 33, 3031 Kaunas, Lithuania.
Medicina (Kaunas). 2003;39(1):15-20.
Electrocardiographic (ECG) evidence of cardiac ischemia or infarction is difficult to detect in the presence of left bundle branch block (LBBB). Traditional ECG indicators of ischemia, such as ST- segment elevation, are common in LBBB and may not indicate acute ischemia. Proper evaluation of the initial ECG is crucial in selecting candidates for early thrombolysis, because the earlier reperfusion treatment is administred, the better are the results. Individuals with LBBB are particularly important stratum of patients to identify. This is true not only because they have a high baseline mortality and receive the greatest incremental improvement in survival when given thrombolytic agents but also because it is tendency to undertreat them. The criteria of Sgarbosa are too insensitive to be used as screening (roule out) test to determine which patients with an LBBB do not have an AMI. The Sgarbosa criteria are, however, highly specific and can be used reliably as confirmatory test to rule in AMI in patients with LBBB. ECG alone doesn't support the diagnosis of AMI. Elevated value of biochemical markers of myocardial necrosis in the presence of LBBB confirms the diagnosis. Despite the recently updated joint practical guidelines of American Heart Association (AHA) and American College of Cardiology (ACC) which defines that all patients having symptoms consistent with acute MI and LBBB should be treated like ST-segment elevation, only minority of them receive thrombolytic therapy, particularly the elderly (only 4%). In the absence of definitive diagnosis of AMI doctors withhold from decision to administer thrombolytic treatment because of risk of haemorrhagic complications. There are not perfect diagnostic tools allowing early diagnostic of AMI in patients having LBBB. Currently the best justified strategy is to follow AHA/ACC recommended guidelines to administer thrombolysis to all patients with LBBB presenting with chest pain, particularly if serum biomarkers are elevated.
在存在左束支传导阻滞(LBBB)的情况下,很难检测到心脏缺血或梗死的心电图(ECG)证据。缺血的传统心电图指标,如ST段抬高,在LBBB中很常见,可能并不表明急性缺血。对初始心电图进行正确评估对于选择早期溶栓治疗的候选人至关重要,因为再灌注治疗开始得越早,效果越好。患有LBBB的个体是特别重要的患者群体,需要识别出来。这不仅是因为他们有较高的基线死亡率,在接受溶栓药物治疗时生存率有最大程度的提高,还因为他们往往得不到充分治疗。Sgarbosa标准作为筛选(排除)试验来确定哪些LBBB患者没有急性心肌梗死(AMI)过于不敏感。然而,Sgarbosa标准具有高度特异性,可可靠地用作确诊试验,以判定LBBB患者是否患有AMI。仅凭心电图不能支持AMI的诊断。在LBBB存在的情况下,心肌坏死生化标志物值升高可确诊。尽管美国心脏协会(AHA)和美国心脏病学会(ACC)最近更新的联合实用指南规定,所有有急性心肌梗死症状且伴有LBBB的患者应按照ST段抬高进行治疗,但只有少数患者接受溶栓治疗,尤其是老年人(仅4%)。在没有明确诊断AMI的情况下,医生因担心出血并发症而不决定给予溶栓治疗。目前尚无完美的诊断工具可对患有LBBB的患者进行AMI的早期诊断。目前最合理的策略是遵循AHA/ACC推荐的指南,对所有有胸痛症状且伴有LBBB的患者进行溶栓治疗,特别是在血清生物标志物升高的情况下。